A report from doctors and scientists highlights the potential of mifepristone in preventing breast cancer. Although smaller studies indicated mifepristone could limit progesterone’s effects linked to breast cancer cell growth, pharmaceutical companies hesitate to pursue further research due to abortion controversies. Experts argue that mifepristone deserves more comprehensive investigation as a non-surgical prevention option. They express disappointment over regulatory obstacles and stress the drug's potential, especially for people with inherited mutations, urging for more focus on its wide-ranging benefits for public health.
"It is deeply disappointing that the successful application of mifepristone in one area of clinical medicine is hindering more extensive research into other indications that could benefit public health."
"We have very promising data, but are being made to continue with the research... The regulatory hurdles are absurd, probably because it is associated with induced abortion."
Collection
[
|
...
]